Ablynx NV has started a Phase 1 study in healthy volunteers of an antibody-derived therapeutic protein for the treatment of respiratory syncytial viral infections. To date, there is only one approved antibody therapeutic for this disease. ---Subscribe to MedNous to access this article--- Research & University News Company News
